Navigation Links
Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
Date:2/20/2009

nes, found in CLL. In 41 patients, MBL was confirmed by both methods.

The study, titled "B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia," (Vol. 360, No. 7, Feb. 12, 2009) was accompanied by the editorial "The Secret Lives of Monoclonal B Cells."

About Quest Diagnostics and Blood-based Tumor Testing

Quest Diagnostics is a leader in noninvasive blood-based biomarker testing used by physicians to screen for, diagnose and monitor carcinomas and other tissue-based disease. The company's proprietary Leumeta(TM) portfolio of tests helps physicians identify and analyze genetic components of leukemia and lymphoma tumors using blood plasma instead of bone marrow, which can only be tested after extraction through painful biopsy. In addition, the company is the exclusive national reference laboratory provider of the blood-based HE4 Ovarian Cancer Monitoring test, which is FDA cleared as an aid in monitoring recurrent or progressive disease in women with epithelial ovarian cancer. The company is also developing a molecular blood test based on Epigenomics AG's Septin 9 DNA methylation biomarker that can help physicians detect colorectal cancer based on a patient's blood specimen.

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.questdiagnostics.com.


'/>"/>
SOURCE Quest Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
4. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
5. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
6. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
7. BioMosaics Glypican-3 Blood & Tissue Tests Receive CE Marking in Europe
8. Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in Miami
9. AspenBio Pharma Reports Strong Results with Appendicitis Triage Blood Test from Large Multiple Hospital Study
10. Microlifes Home Blood Pressure Monitors Proven Accurate Even for Critical Patients
11. WaveSense Blood Glucose Meter One of Few Brands to Pass Rigorous TNO Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Calif., Dec. 4 Vermillion, Inc. (VRML) (Pink Sheets: VRMLQ) ... Amended Plan of Reorganization and related amended Disclosure Statement with ... ,, A hearing to consider the adequacy of ... with the hearing on the confirmation of the Plan scheduled ...
(Date:12/4/2009)... Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that ... Principal investigators will discuss the data presentations surrounding carfilzomib ... the 51st American Society of Hematology (ASH) Annual Meeting. ... a.m. ET on Monday, December 7, 2009. The ...
(Date:12/4/2009)... Shared Imaging, LLC, an independent provider of CT, ... hospitals and healthcare providers, is excited to announce ... Ambulatory Health Care, a nationally-recognized, prestigious gold seal ... care. Shared Imaging accreditation is system-wide for its ...
Breaking Medicine Technology:Vermillion Files Amended Plan of Reorganization and Exchanges Debt 2Vermillion Files Amended Plan of Reorganization and Exchanges Debt 3Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2Shared Imaging Earns The Joint Commission's Accreditation for Ambulatory Health Care 2New research program BioInterfaces launched 8742 1New research program BioInterfaces launched 8742 2Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 1Quest Diagnostics to Speak at the William Blair 26 Company 29th Annual Growth Stock Conference 48179 2Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 1Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 2Sinovac Begins the Production of Influenza A 28H1N1 29 Vaccine 12524 3
... CAMBRIDGE, Mass., and BERLIN, Sept. 26 ,Genzyme Corporation ... AG, Germany,today announced that the first patient has ... 3 trials examining the safety and efficacy of ... The CARE-MS I trial (Comparison of Alemtuzumab and ...
... 26 Innocoll, Inc., a privately-held,specialty pharmaceutical company, ... clinical development programs and specialty,pharmaceutical operations: - ... in 2007., - GENTAMICIN ... multi-centered clinical trials for the ...
Other Medicine Technology:Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 2Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 3Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 4Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 5Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 6Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 2Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 3Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 4Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 5Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations 6
(Date:12/5/2009)... new three-drug combination has shown in a phase 1/2 ... regimen" in the treatment of patients newly diagnosed with ... bone marrow, say researchers from Dana-Farber Cancer Institute. , ... the 66 patients treated with the drug combination in ... good partial response rate" in the phase 2 population, ...
(Date:12/5/2009)... Blood Cancer Is Most Challenging-- ,, PHILADELPHIA ... identified specific genes, dubbed partner genes, that fuse with ... in infants. By more accurately defining specific partner genes, ... from particular treatments. ,, Oncologists also aim to ...
(Date:12/5/2009)... Midbrook,s advanced Technology Center helps companies develop and test their cleaning ... in a variety of industries and solve problems for customers relating ... ... (Vocus) December 5, 2009 -- Midbrook, Inc , a Jackson, ...
(Date:12/4/2009)... Systems (NYSE: VAR ) announced today that its ... of Stockholders for February 11, 2010 with a record date ... the Crowne Plaza Cabana Hotel, 4290 El Camino Real, Palo ... be webcast by Thomson Financial and can be accessed at ...
(Date:12/4/2009)... Holdings, Ltd (NYSE: AWH ) today announced ... Sennott, Executive Vice,President and Chief Corporate Strategy Officer, will ... Conference being held at the Goldman,Sachs Conference Center in ... About Allied World Assurance Company ...
Breaking Medicine News(10 mins):Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 2Health News:Midbrook Lab Testing Provides Results for Cleaning Process Develop and Verification 3Health News:Varian Medical Systems Schedules Annual Stockholder Meeting in Palo Alto 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2
... MA--The National Institutes of Health (NIH) has awarded one ... 2008 to a team based at Boston University Medical ... (BMC). These awards, together with 12 CTSAs awarded in ... of an NIH effort to build a national consortium ...
... the focus of the Staying Sharp session on June 3 ... recognized series, the program will emphasize successful aging, including how ... future cognitive function; and the importance of clinical trials and ... member Marwan N. Sabbagh will sign copies of his book, ...
... Pa., May 29 The Pennsylvania,Department of Health today ... 31,observance of "World No Tobacco Day," which is designed ... "Exposure to secondhand smoke causes disease and premature death ... Calvin B.,Johnson. "I encourage all Pennsylvania smokers to set ...
... Ensure Patients Receive High-Value Health Care, WASHINGTON, ... care spending and improve the quality of patient ... Insurance Plans (AHIP) was,implemented. PricewaterhouseCoopers reviewed AHIP,s proposals ... fully implemented, the nation,s,total health care expenditures could ...
... Vanessa Carlton to Help ... Cancer Leader, WASHINGTON, May 29 Breast cancer ... Carlton will join Susan G. Komen for the Cure(R) ... activities leading up to the,19th annual Susan G. Komen ...
... Access by Breaking Through Barriers, NEWPORT NEWS, ... Patient Advocate Foundation today announced a strategic,collaboration that ... families,quick access to timely information and specialized patient ... lives of cancer,patients nationwide who are facing access ...
Other Medicine News:Health News:BUMC, BMC receives Clinical and Translational Science Award from NIH 2Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 2Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 3Health News:AHIP Outlines Plan to Reduce Health Care Costs by $145 Billion 4Health News:Susan G. Komen for the Cure(R) Celebrity Ambassadors to Convene in Nation's Capital to Help Race for the Cure, End Breast Cancer Forever 2Health News:American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients 2Health News:American Cancer Society, Patient Advocate Foundation Announce Free, Personalized Assistance for Cancer Patients 3
The Express Plus clinical chemistry analyzer is a fully automated walk away system designed for maximum productivity, convenience and reliability....
Seamlessly integrates with the i2000SR to form a state-of-the-art immunochemistry platform, the ci8200. Flexibility to prioritize STAT, automated rerun/dilution, and reflex testing over routines to e...
... and controls interchangeable with other Roche/Hitachi ... training costs. Consistent patient results throughout ... handling. 70 positions for routine, STAT ... volumes. Intermix sample types. Intermix 5 ...
Modular Pre-Analytics is an integral component of the new modular systems platform which combines pre-analytics, clinical chemistry and immunochemistry....
Medicine Products: